Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, 061000, Hebei, China.
Drugs R D. 2022 Dec;22(4):271-279. doi: 10.1007/s40268-022-00402-6. Epub 2022 Sep 22.
Aspirin is a common drug for the treatment of pre-eclampsia. We aimed to explore whether quercetin as a supplement to aspirin could enhance the therapeutic outcome in pre-eclampsia rat models. We further aimed to evaluate the nucleotide-binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome as a potential pre-eclampsia-related molecular mechanism, which can be affected by quercetin treatment.
Rat pre-eclampsia models were established using an intravenous lipopolysaccharide injection after gestation. Rats were treated with aspirin and quercetin at 6-18 days after pregnancy. On day 20, blood, fetus, and placenta were harvested. Blood pressure and the level of proteinuria were measured every 4 days. Fetal outcomes were analyzed by pup body weight. Serum soluble Fms-like tyrosine kinase-1, PIGF, interleukin-6, and interleukin-10 levels were measured using the enzyme-linked immunosorbent assay. Caspase-1, NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain, and p-caspase-1 levels in the placenta were assessed using western blot or quantitative real-time polymerase chain reaction analyses.
Pre-eclampsia rat models showed a pronounced increase in systolic blood pressure and proteinuria after 4 days of pregnancy, while aspirin, quercetin, and aspirin/quercetin combinatory treatment significantly attenuated the blood pressure and proteinuria abnormalities. Notably, the aspirin/quercetin combinatory treatment showed the highest efficacy in attenuating pre-eclampsia-like symptoms. Placental caspase-1 and NLRP3 levels also showed the greatest attenuation in pre-eclampsia rats after aspirin/quercetin treatment.
Our data suggested that quercetin supplementation to aspirin is more effective in attenuating symptoms of pre-eclampsia and improving pregnancy outcomes compared with quercetin or aspirin alone. Quercetin can ameliorate placental NLRP3 inflammasome activation, which might serve as an underlying mechanism for its therapeutic efficacies in pre-eclampsia.
阿司匹林是治疗子痫前期的常用药物。我们旨在探讨将槲皮素作为阿司匹林的补充剂是否可以增强子痫前期大鼠模型的治疗效果。我们还旨在评估核苷酸结合寡聚化结构域样受体家族,含吡咯并嘧啶结构域蛋白 3(NLRP3)炎症小体作为一种潜在的子痫前期相关分子机制,该机制可能受槲皮素治疗的影响。
通过在妊娠后静脉内注射脂多糖建立大鼠子痫前期模型。在妊娠后 6-18 天,用阿司匹林和槲皮素对大鼠进行治疗。第 20 天,采集血液、胎儿和胎盘。每 4 天测量一次血压和蛋白尿水平。通过幼仔体重分析胎儿结局。使用酶联免疫吸附试验测定血清可溶性 Fms 样酪氨酸激酶-1、胎盘生长因子、白细胞介素-6 和白细胞介素-10 水平。使用蛋白质印迹或实时定量聚合酶链反应分析评估胎盘中的半胱氨酸蛋白酶-1、NLRP3、凋亡相关斑点样蛋白含有半胱氨酸蛋白酶募集结构域和 p-半胱氨酸蛋白酶-1 水平。
子痫前期大鼠模型在妊娠第 4 天出现明显的收缩压和蛋白尿升高,而阿司匹林、槲皮素和阿司匹林/槲皮素联合治疗可显著减轻血压和蛋白尿异常。值得注意的是,阿司匹林/槲皮素联合治疗在减轻子痫前期样症状方面效果最佳。胎盘半胱氨酸蛋白酶-1 和 NLRP3 水平在子痫前期大鼠经阿司匹林/槲皮素治疗后也有最大程度的降低。
我们的数据表明,与单独使用槲皮素或阿司匹林相比,阿司匹林联合槲皮素治疗可更有效地减轻子痫前期症状,改善妊娠结局。槲皮素可改善胎盘 NLRP3 炎症小体的激活,这可能是其在子痫前期治疗中的疗效的潜在机制。